Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update
Background: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents....
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Portuguesa de Reumatologia
2017-04-01
|
Series: | Acta Reumatológica Portuguesa |
Subjects: | |
Online Access: | http://www.actareumatologica.com/files/article/1175_portuguese_recommendations_for_the_use_of_methotrexate_in_rheumatic_diseases_2016_update_file.pdf |
id |
doaj-7a1f9fa5da2248019f0b7b4db6e2af64 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ana Catarina Duarte Daniela Santos-Faria Maria João Gonçalves Alexandre Sepriano Ana Filipa Mourão Cátia Duarte Joana Sousa Neves Ana Filipa Águeda Pedro Avila Ribeiro Alexandra Daniel Adriano Neto Ana Cordeiro Ana Rodrigues Anabela Barcelos Cândida Silva Cristina Ponte Elsa Vieira-Sousa Filipa Teixeira Filipa Oliveira-Ramos Filipe Araújo Filipe Barcelos Helena Canhão Helena Santos João Ramos Joaquim Polido-Pereira José Tavares-Costa José António Melo Gomes Luís Cunha-Miranda Lúcia Costa Marcos Cerqueira Margarida Cruz Maria José Santos Miguel Bernardes Paula Oliveira Pedro Abreu Ricardo Figueira Rita Barros Sandra Falcão Patrícia Pinto Sofia Pimenta Susana Capela Vitor Teixeira João Eurico Fonseca |
spellingShingle |
Ana Catarina Duarte Daniela Santos-Faria Maria João Gonçalves Alexandre Sepriano Ana Filipa Mourão Cátia Duarte Joana Sousa Neves Ana Filipa Águeda Pedro Avila Ribeiro Alexandra Daniel Adriano Neto Ana Cordeiro Ana Rodrigues Anabela Barcelos Cândida Silva Cristina Ponte Elsa Vieira-Sousa Filipa Teixeira Filipa Oliveira-Ramos Filipe Araújo Filipe Barcelos Helena Canhão Helena Santos João Ramos Joaquim Polido-Pereira José Tavares-Costa José António Melo Gomes Luís Cunha-Miranda Lúcia Costa Marcos Cerqueira Margarida Cruz Maria José Santos Miguel Bernardes Paula Oliveira Pedro Abreu Ricardo Figueira Rita Barros Sandra Falcão Patrícia Pinto Sofia Pimenta Susana Capela Vitor Teixeira João Eurico Fonseca Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update Acta Reumatológica Portuguesa portugal methotrexate rheumatoid arthritis rheumatic diseases recommendations |
author_facet |
Ana Catarina Duarte Daniela Santos-Faria Maria João Gonçalves Alexandre Sepriano Ana Filipa Mourão Cátia Duarte Joana Sousa Neves Ana Filipa Águeda Pedro Avila Ribeiro Alexandra Daniel Adriano Neto Ana Cordeiro Ana Rodrigues Anabela Barcelos Cândida Silva Cristina Ponte Elsa Vieira-Sousa Filipa Teixeira Filipa Oliveira-Ramos Filipe Araújo Filipe Barcelos Helena Canhão Helena Santos João Ramos Joaquim Polido-Pereira José Tavares-Costa José António Melo Gomes Luís Cunha-Miranda Lúcia Costa Marcos Cerqueira Margarida Cruz Maria José Santos Miguel Bernardes Paula Oliveira Pedro Abreu Ricardo Figueira Rita Barros Sandra Falcão Patrícia Pinto Sofia Pimenta Susana Capela Vitor Teixeira João Eurico Fonseca |
author_sort |
Ana Catarina Duarte |
title |
Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update |
title_short |
Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update |
title_full |
Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update |
title_fullStr |
Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update |
title_full_unstemmed |
Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update |
title_sort |
portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update |
publisher |
Sociedade Portuguesa de Reumatologia |
series |
Acta Reumatológica Portuguesa |
issn |
0303-464X |
publishDate |
2017-04-01 |
description |
Background: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents.
Objectives: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009.
Methods: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations.
Results: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment.
Conclusion: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice. |
topic |
portugal methotrexate rheumatoid arthritis rheumatic diseases recommendations |
url |
http://www.actareumatologica.com/files/article/1175_portuguese_recommendations_for_the_use_of_methotrexate_in_rheumatic_diseases_2016_update_file.pdf |
work_keys_str_mv |
AT anacatarinaduarte portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT danielasantosfaria portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT mariajoaogoncalves portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT alexandresepriano portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT anafilipamourao portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT catiaduarte portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT joanasousaneves portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT anafilipaagueda portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT pedroavilaribeiro portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT alexandradaniel portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT adrianoneto portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT anacordeiro portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT anarodrigues portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT anabelabarcelos portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT candidasilva portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT cristinaponte portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT elsavieirasousa portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT filipateixeira portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT filipaoliveiraramos portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT filipearaujo portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT filipebarcelos portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT helenacanhao portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT helenasantos portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT joaoramos portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT joaquimpolidopereira portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT josetavarescosta portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT joseantoniomelogomes portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT luiscunhamiranda portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT luciacosta portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT marcoscerqueira portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT margaridacruz portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT mariajosesantos portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT miguelbernardes portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT paulaoliveira portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT pedroabreu portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT ricardofigueira portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT ritabarros portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT sandrafalcao portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT patriciapinto portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT sofiapimenta portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT susanacapela portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT vitorteixeira portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update AT joaoeuricofonseca portugueserecommendationsfortheuseofmethotrexateinrheumaticdiseases2016update |
_version_ |
1725523545362006016 |
spelling |
doaj-7a1f9fa5da2248019f0b7b4db6e2af642020-11-24T23:36:27ZengSociedade Portuguesa de ReumatologiaActa Reumatológica Portuguesa0303-464X2017-04-0120172127140PC170012Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 updateAna Catarina Duarte0Daniela Santos-Faria1Maria João Gonçalves2Alexandre Sepriano3Ana Filipa Mourão4Cátia Duarte5Joana Sousa Neves6Ana Filipa Águeda7Pedro Avila Ribeiro8Alexandra Daniel9Adriano Neto10Ana Cordeiro11Ana Rodrigues12Anabela Barcelos13Cândida Silva14Cristina Ponte15Elsa Vieira-Sousa16Filipa Teixeira17Filipa Oliveira-Ramos18Filipe Araújo19Filipe Barcelos20Helena Canhão21Helena Santos22João Ramos23Joaquim Polido-Pereira24José Tavares-Costa25José António Melo Gomes26Luís Cunha-Miranda27Lúcia Costa28Marcos Cerqueira29Margarida Cruz30Maria José Santos31Miguel Bernardes32Paula Oliveira33Pedro Abreu34Ricardo Figueira35Rita Barros36Sandra Falcão37Patrícia Pinto38Sofia Pimenta39Susana Capela40Vitor Teixeira41João Eurico Fonseca42Hospital Garcia de Orta, AlmadaUnidade Local de Saúde do Alto Minho, Ponte de LimaHospital de Santa Maria, Centro Hospitalar Lisboa Norte; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, LisbonHospital Egas Moniz, Centro Hospitalar Lisboa Ocidental, LisbonHospital Egas Moniz, Centro Hospitalar Lisboa Ocidental; CEDOC - Nova Medical School, Universidade Nova de Lisboa; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbonon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of Rheumatologyon behalf of the Portuguese Society of RheumatologyBackground: Methotrexate (MTX) is the first-line drug in the treatment of rheumatoid arthritis (RA) and the most commonly prescribed disease modifying anti-rheumatic drug. Moreover, it is also used as an adjuvant drug in patients under biologic therapies, enhancing the efficacy of biologic agents. Objectives: To review the literature and update the Portuguese recommendations for the use of MTX in rheumatic diseases first published in 2009. Methods: The first Portuguese guidelines for the use of MTX in rheumatic diseases were published in 2009 and were integrated in the multinational 3E Initiative (Evidence Expertise Exchange) project. The Portuguese rheumatologists based on literature evidence and consensus opinion formulated 13 recommendations. At a national meeting, the recommendations included in this document were further discussed and updated. The document resulting from this meeting circulated to all Portuguese rheumatologists, who anonymously voted online on the level of agreement with the updated recommendations. Results: Results presented in this article are mainly in accordance with previous guidelines, with some new information regarding hepatitis B infection during MTX treatment, pulmonary toxicity monitoring, hepatotoxicity management, association with hematologic neoplasms, combination therapy and tuberculosis screening during treatment. Conclusion: The present recommendations combine scientific evidence with expert opinion and attained desirable agreement among Portuguese rheumatologists. The regular update of these recommendations is essential in order to keep them a valid and useful tool in daily practice.http://www.actareumatologica.com/files/article/1175_portuguese_recommendations_for_the_use_of_methotrexate_in_rheumatic_diseases_2016_update_file.pdfportugalmethotrexaterheumatoid arthritisrheumatic diseasesrecommendations |